Non-Small Cell Lung Cancer KOL Interview – NH, US
Author: Datamonitor Healthcare
Datamonitor Healthcare interviewed a US-based oncologist with clinical trial and commercial experience of PD-1/L1 inhibitors to gauge his views on their current application within non-small cell lung cancer (NSCLC), and the potential broader development of immuno-oncology approaches and biomarkers within the indication.
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email email@example.com for further help or assistance.